For the estimated 1.2 million people living with HIV who develop tuberculosis annually — a population at dramatically elevated mortality risk — the diagnostic gap between available point-of-care tools and actual disease burden remains dangerously wide. An improved lateral flow assay that closes even a fraction of that gap while delivering consistent manufacturing performance could meaningfully shift outcomes in high-burden settings where sputum-based testing is often impractical.
The FujiLAM II, a redesigned version of Fujifilm's lipoarabinomannan-detecting urine assay, was evaluated against biobanked specimens from 798 HIV-positive inpatients and outpatients across two prospective hospital studies in Cameroon. Among 119 participants with microbiologically confirmed tuberculosis — verified against a composite reference standard combining dual sputum liquid cultures and multi-matrix Xpert Ultra testing — FujiLAM II achieved 49% sensitivity and 96% specificity. Its predecessor, AlereLAM, reached only 35% sensitivity and 92% specificity on the same specimens. Critically, the redesigned assay showed no statistically significant performance variation across four distinct manufacturing lots, addressing a known reliability weakness of the original platform.
These results are clinically meaningful but demand careful framing. A 49% sensitivity means roughly half of confirmed TB cases would be missed by FujiLAM II used alone — a limitation the assay shares with most urine LAM-based diagnostics, which perform substantially better in severely immunocompromised individuals (CD4 <100 cells/µL). The specificity improvement over AlereLAM, however, reduces false positives and the unnecessary treatment burden they carry. The lot-to-lot consistency finding is arguably the study's most operationally significant contribution: inconsistent batch performance has historically undermined field deployment of lateral flow assays in low-resource settings. This is a single-center African cohort using biobanked specimens, which introduces storage-related analyte degradation as a confound. Prospective evaluation across CD4-stratified subgroups and in community settings would strengthen the implementation case. Incremental rather than transformative, but the consistency data represent a genuine manufacturing advance.